London-based Clarivate (NYSE:CLVT), a global provider of transformative intelligence solutions for scientific research, intellectual property, and life sciences, reported fourth-quarter and full-year 2025 results on February 24, 2026, highlighting enhanced cash generation, progress in subscription-based revenue mix, and strategic actions to streamline the portfolio and strengthen the balance sheet.
For the full year 2025, total revenue reached $2,455.2 million.
Organic Annual Contract Value (ACV), a key metric reflecting subscription momentum, increased 1.8% year-over-year, driven by solid retention and new sales in core segments including Intellectual Property, Science & Academia, and select Life Sciences offerings.
Free cash flow for 2025 improved significantly to $365.3 million, reflecting disciplined cost management, working capital efficiencies, and reduced capital intensity following prior divestitures and operational streamlining.
Clarivate also announced it is pursuing a strategic sale process for its Life Sciences & Healthcare business, aiming to unlock value and focus resources on higher-growth, higher-margin core operations in intellectual property management, scientific research, and academic solutions.